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Recombinant vaccinia viruses have shown promise as vaccine vectors. However, their effectiveness is markedly reduced by pre-existing anti-
vaccinia immunity. The possibility of new vaccinia immunizations in the event of a bioterror-related smallpox release poses an additional negative
impact on the utility of vaccinia-based vectors. Thus, we aimed to design a vaccinia vector that would enhance the immune response to an
expressed foreign protein in a pre-immune animal model. To do this, we made use of the finding that most neutralizing antibodies against the
extracellular form of vaccinia virus are directed against the B5 protein. We found that mice immunized with vaccinia, primed with Gag plasmid
DNA, and boosted with a recombinant vaccinia virus lacking the majority of the B5 ectodomain expressing a test antigen, HIV Gag, had stronger
anti-Gag immune responses than mice that were boosted with a wild-type virus-expressing Gag. These findings are particularly striking given the
more attenuated phenotype of this virus, as compared to its wild-type counterpart. Importantly, we found that vaccination with a B5R deletion
virus, followed by boosting with the Gag-expressing virus lacking the majority of the B5 ectodomain, resulted in poorer anti-Gag immune
responses. Thus, recombinant vaccinia viruses lacking the B5 ectodomain may serve as vaccine vectors in DNA prime-vaccinia boost vaccinations
of individuals with pre-existing immunity against vaccinia. These data open the possibility of extending the potential benefit of replication
competent recombinant vaccinia virus vectors to a larger population.
© 2006 Elsevier Inc. All rights reserved.Keywords: Vaccinia virus; Immunity; B5 protein; Recombinant vector; Vaccines; DNA; MiceIntroduction
Recombinant vaccinia viruses are appealing vaccine vectors
for several reasons: they generate potent antibody and T cell
responses, their large cloning capacity allows for the expression
of multiple foreign genes, they have a wide host and cell range,
and they form stable recombinants (Moroziewicz and Kaufman,
2005). Vaccinia-based vectors have been constructed as vaccine
candidates against a number of infectious diseases including
HIV, tuberculosis, and malaria, and have been used in
immunotherapies against cancer (e.g., Ami et al., 2005;
Mastrangelo et al., 2000; Rochlitz et al., 2003; Shen and
Nemunaitis, 2005). Official approval has been granted for the
use of a vaccinia-based vaccine to protect wildlife against the
rabies virus (Pastoret and Brochier, 1996). Importantly, the use⁎ Corresponding author. Fax: +1 214 349 5111.
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doi:10.1016/j.virol.2006.11.020of vaccinia vectors to combat various diseases has illustrated
that the virus is relatively well tolerated. Attenuated strains of
vaccinia, such as modified vaccinia virus Ankara (MVA), have
been employed to further promote the safety of vaccinia-based
vectors (Shen and Nemunaitis, 2005). To enhance immune
responses to vaccinia virus vectors, a strategy of priming with
DNA prior to poxvirus boosting has been employed (Gilbert et
al., 2005; Hanke et al., 1999; McShane et al., 2001; Sullivan et
al., 2000).
While the potent immune responses elicited by vaccinia
virus are helpful for the development of memory T and B cells
specific for a foreign antigen, there is a drawback to the
immunogenicity elicited by this virus. Until the World Health
Organization successfully eradicated smallpox in the 1970s, the
smallpox vaccine was used as a standard childhood vaccine
(Mahalingam et al., 2004). As demonstrated by Hammarlund et
al., antiviral immunity against vaccinia remains high for several
decades post vaccination (Hammarlund et al., 2003). This long-
Fig. 1. Gag-specific T cell activation after boosting of vaccinia immune mice
with vvWT-gag, vvΔB5-gag, or WT viruses. All mice were initially immunized
with WT vaccinia virus. Two weeks later, groups of mice (5 mice/group) were
either treated (black bar) or untreated (white bar) with Gag DNA, and then
boosted 2 weeks later with vvWT-gag, vvΔB5-gag, or WT viruses. Splenocytes
were stimulated for 24 h in the presence of control peptides, or (A) a class I Gag
epitope, or (B) a class II Gag epitope. Gag-specific IFN-γ producing cells were
quantitated by ELISpot. The number of positive cells in wells receiving control
peptide was subtracted from those receiving Gag. Shown are the means±SEM
of mice in each group for each condition. This experiment was performed three
times with similar results (*, p<0.05 compared with vvWT-gag or WT virus).
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number of people who could fully benefit from a vaccinia-based
vaccine therapy (e.g., Cooney et al., 1991). A further hindrance
to the future use of vaccinia-based vectors will arise if mass
vaccination is reinstated as a countermeasure against bioterror-
ism with smallpox (Halloran et al., 2002).
There are two infectious forms of vaccinia virus: mature
virus (MV) and extracellular virus (EV). MV represents the
majority of progeny virus formed during an infection and EV,
though less abundant, is critical for dissemination and spread
within the infected host (Smith et al., 2002). Neutralizing
antibodies against both virus forms are required for optimal
protection from poxvirus infections (Appleyard and Andrews,
1974; Turner and Squires, 1971). The EV-specific B5 protein
was recently shown to be the primary target of EV-neutralizing
antibodies (Bell et al., 2004). Indeed, a mutant vaccinia virus
lacking the majority of the B5 ectodomain, but making nearly
wild-type levels of EV, is resistant to neutralization by vaccinia
immune globulin (Bell et al., 2004). Based on this information,
we hypothesized that a virus lacking the B5 ectodomain would
be less readily cleared by a vaccinia-experienced immune
system, making it a more efficient vector to express a foreign
protein than a wild-type (WT) virus expressing the same foreign
antigen. In this study, pre-immune mice were given a single
HIV-1 Gag DNA prime and then boosted with a WT or B5
mutant virus that each expressed the same foreign protein, HIV-
1 Gag. Importantly, we found that while the virus lacking the
majority of the B5 ectodomain is attenuated in vivo, it elicits a
more potent anti-Gag immune response than its WTcounterpart.
This proof of concept finding should help pave the way for the
development of replication competent vaccinia-based vector
approaches that can be utilized in individuals with pre-existing
immunity to vaccinia.
Results
After DNA prime, boosting of pre-immune mice with
vvΔB5-gag induced a stronger anti-Gag immune response
than vvWT-gag
Because pre-existing vaccinia virus immunity blunts the
immune response to foreign proteins expressed by recombinant
vaccinia viruses, we sought to test a vaccinia vector that might
still generate responses. DNA priming has been show to enhance
the immune response to poxvirus vectors (Gilbert et al., 2005;
Hanke et al., 1999; McShane et al., 2001; Sullivan et al., 2000),
and has even been used to enhance the immune responses in
vaccinia immune hosts (Yang et al., 2003). However, this
strategy requires multiple DNA treatments (Yang et al., 2003).
Thus, as a proof of concept, we sought to design a vaccinia
vector that could work after a single DNA prime. This new
vector design was based on evidence that the major EV-
neutralizing activity is directed against the B5 protein (Bell et al.,
2004). Our aimwas to determine if boosting of pre-immunemice
with vvΔB5-gag could promote enhanced expression of the Gag
protein due to escape of this virus from pre-existing anti-B5
neutralizing antibodies. Thus, we first immunized mice withwild-type vaccinia virus to generate vaccinia immune mice. Two
weeks later, we primed some groups of mice with a single
injection of an early generation Gag-expressing DNA vaccine
(Qiu et al., 1999). Four weeks after the initial vaccinia virus
immunization, we boosted the mice with vvWT-gag, vvΔB5-
gag, or WT control virus. We quantitated the number of Gag-
specific IFN-γ producing CD4+ and CD8+ T cells 2 weeks post
boost. As shown in Fig. 1, little to no response was measured in
vaccinia immune mice in the absence of Gag DNA priming.
Vaccinia immune mice primed with DNA and then boosted with
vvΔB5-gag had significantly higher CD8+ and CD4+ Gag
responses than mice boosted with vvWT-gag (Figs. 1A and B).
Indeed, vvWT-gag failed to stimulate a measurable response
over background IFN-γ production induced by the WT vaccinia
boost of pre-immune mice. We hypothesized that pre-existing
anti-B5 immunity in vaccinia immune mice resulted in more
rapid clearance of the vvWT-gag after challenge, thus preventing
establishment of an immune response to Gag. vvΔB5-gag, in
contrast, was able to establish enough of an infection to allow
anti-Gag responses to develop.
vvWT-gag and vvΔB5-gag are both highly attenuated in vivo
To insure that differences in the strength of the anti-Gag T
cell responses mounted against infection with vvWT-gag versus
vvΔB5-gag did not result from discrepancies in the virulence
358 K.M. Viner et al. / Virology 361 (2007) 356–363and/or inherent immunogenicity of these two recombinants, we
infected groups of naïve mice with either virus and assessed their
virulence by measuring weight and quantitating viral titers in
organs. As shown in Fig. 2A, groups of mice infected
intranasally with a high titer of vvWT-gag or vvΔB5-gag failed
to lose weight. These mice appeared healthy and did not show
any signs of illness. This is not surprising considering that both
viruses are TK-minus, which is known to result in severe
attenuation in mice (Buller et al., 1985; Phillpotts et al., 2000).
Livers and spleens harvested from infected mice at various times
post infection failed to show evidence of viral dissemination,
consistent with the severe attenuation of these viruses. However,
we were able to titer virus out of the lungs at days 3 and 5 post
infection (Fig. 2B). Importantly, vvWT-gag infection resulted in
consistently higher viral titers than vvΔB5-gag infection at both
time points. While the mutant virus lacking the majority of the
B5 ectodomain makes nearly wild-type levels of EV in tissue
culture (Herrera et al., 1998; Mathew et al., 1998), the highly
conserved ectodomain of B5 in orthopoxviruses indicates that
the deleted region may have other important in vivo functions
that contributed to the further attenuation we found. Thus,
vvΔB5-gag provides enhanced anti-Gag immune responses, but
is even more attenuated than vvWT-gag. We next examined the
anti-vaccinia virus immune responses generated in these groupsFig. 2. Pathogenesis and vaccinia-specific immune responses to vvWT-gag and vvΔB
gag or vvΔB5-gag and (A) percent weight change was measured over time. (B) T
quantitated in the lungs. (C) Five mice in each group were sacrificed 6 weeks after intr
(D) Splenocytes from these sacrificed mice were co-cultured with naïve antigen pr
uninfected (Uninfect APC) and IFN-γ producing cells were quantitated by ELISpot
experiments were performed two times with similar results (*, p<0.05 compared wof mice. While vvWT-gag and vvΔB5-gag induced equivalent
anti-vaccinia antibody responses after infection (Fig. 2C),
vvWT-gag produced a stronger cellular immune response to
vaccinia (Fig. 2D). Our finding that vvWT-gag is, if anything,
more virulent and leads to better anti-vaccinia virus cellular
immune responses than vvΔB5-gag lends more credence to our
hypothesis that the anti-Gag response elicited by vvΔB5-gag in
vaccinia immune mice is the result of delayed clearance in the
absence of a B5 target for anti-B5 antibodies.
Primary vaccination with vvB5R-KO virus prevents induction
of a strong anti-Gag immune response upon boosting with
vvΔB5-gag
To provide further evidence that the pre-existing anti-B5
antibodies had a greater effect on Gag immunogenicity
generated by vvWT-gag than by vvΔB5-gag, we examined
the Gag-specific immune responses generated in pre-immune
mice that were immunized with a virus in which the B5R gene is
completely deleted (Wolffe et al., 1993). We hypothesized that
since the B5R deletion virus expresses all other viral proteins, it
should generate vaccinia immune responses except ones
directed at the B5 protein. Since the B5R deletion virus is
highly attenuated (Wolffe et al., 1993), we wanted to ensure that5-gag. Groups of 12 mice were infected intranasally with 5×106 pfu of vvWT-
hree mice in each group were sacrificed at days 3 and 5 and virus titers were
anasal infection and anti-vaccinia virus antibody titers were measured by ELISA.
esenting cells (APC) that had been infected with WT virus (INF APC) or left
. Shown are the means±SEM of mice in each group for each condition. These
ith vvΔB5-gag).
Fig. 3. Anti-vaccinia virus antibody responses in mice vaccinated with wild-type
virus or vvB5R-KO. Groups of four mice were immunized with WT (closed
squares) or vvB5R-KO (open circles) by tail scarification and anti-vaccinia
immune responses were measured by ELISA 1 month after vaccination.
Antibody responses to (A) whole vaccinia virus infected cell lysate, (B) vaccinia
virus MV protein L1, (C) vaccinia virus EV protein A33 were determined.
Shown are the means±SD of sera from individual mice in each group at each
dilution. Closed triangles represent sera from naïve mice.
Fig. 4. Gag-specific T cell activation and anti-vaccinia antibody responses in
mice immunized with WT or B5R-KO viruses and boosted with vvWT-gag,
vvΔB5-gag, or WT viruses. Groups of five mice were immunized with the
indicated virus, primed with Gag DNA, and then boosted with vvWT-gag,
vvΔB5-gag, or WT viruses. Splenocytes were stimulated for 24 h in the
presence of control peptides, (A) a class I Gag epitope, or (B) a class II Gag
epitope. Gag-specific IFN-γ producing cells were quantitated by ELISpot. The
number of positive cells in wells receiving control peptide was subtracted from
those receiving Gag. Shown are the means±SEM of mice in each group for each
condition. These experiments were performed three times with similar results
(*, p<0.05 compared with vvWT-gag boosted; **, p<0.05 compared with
vvΔB5-gag boosted). (C) Sera taken from groups of mice at the time of
splenocyte harvest were analyzed for anti-B5 and anti-A33 IgG antibody
responses by ELISA. Shown are the means (±SEM) of the calculated area under
the curve (AUC) for six serial, 3-fold dilutions from 1:50 to 1:12,150.
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B5R deletion virus could generate similar levels of anti-
vaccinia virus immune responses as the wild-type virus. We
vaccinated groups of mice, bled them 1 month later, and
measured antibody responses to whole vaccinia virus lysate
and individual MV and EV surface proteins. We found similar
anti-vaccinia antibody responses to whole infected cell lysate
(Fig. 3A), baculovirus expressed L1 (Fig. 3B), and baculo-
virus expressed A33 (Fig. 3C). This finding of comparable
immune responses to WT and the full B5R deletion viruses is
similar to what was reported by Jackson et al. in their studies
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a B5R deletion and its parental virus (Jackson et al., 2005).
To test differences in anti-Gag immune responses generated
by vvWT-gag and vvΔB5-gag in pre-immune mice, we
primed groups with Gag DNA 2 weeks after the initial
vaccinia virus vaccinations. Four weeks following the initial
vaccinia immunization, we boosted the mice with vvWT-gag,
vvΔB5-gag, or WT control virus, and quantitated the number
of Gag-specific IFN-γ producing CD8+ and CD4+ T cells 2
weeks later. In contrast to the mice with pre-existing immunity
to vaccinia virus after WT virus vaccination, mice immunized
with vvB5R-KO and boosted with vvΔB5-gag had lower
Gag-specific responses than mice boosted with vvWT-gag
(Figs. 4A and B). Furthermore, we observed the opposite trend
in mice boosted with vvWT-gag (Figs. 4A and B). Since
vvWT-gag is more virulent than vvΔB5-gag, it is possible that in
the absence of a potent anti-B5 antibody response, this virus has
an opportunity to generate better anti-Gag responses. To further
support our hypothesis that the lack of anti-B5 immunity is
responsible for enhanced Gag-specific immunity in mice
boosted with vvΔB5-gag, we also examined the antibody
responses 2 weeks after boosting with the Gag-expressing
viruses. As shown in Fig. 4C, while animals vaccinated withWT
virus and boosted with the Gag-expressing viruses had robust
anti-B5 antibody responses, mice vaccinated with the B5R
deletion virus and boosted with the Gag-expressing viruses
generated little to no anti-B5 antibody.
Discussion
Laboratory studies of vaccinia virus are important because
they provide an increased understanding of its role as a vaccine
against smallpox, and lead to the development of new strategies
for its use as a vaccine vector. The potential future use of
vaccinia as a vaccine vector is at risk of being thwarted in this
new age of biodefense. In general, people born prior to the early
1970s likely had routine smallpox vaccination and thus have
immunity against vaccinia virus. In response to the threat of
bioterrorism with smallpox, there is now the potential that
smallpox vaccination will again become widespread. Given the
promise shown by vaccinia-based vaccines and therapies
against other infectious diseases and cancers, it would be
unfortunate to have to abandon this approach. Because prior
smallpox vaccination does not generate sterilizing immunity,
many strategies will need to rely on the use of replication
competent vaccinia virus vectors (i.e., not MVA) to generate
optimal immune responses to the foreign antigen. Based on our
knowledge of the importance of anti-B5 antibodies in EV
neutralization, we tested the hypothesis as a proof of concept
that vaccinia vectors could be manipulated so that they could
still be utilized in a DNA prime-vaccinia boost strategy in hosts
with pre-existing vaccinia immunity. We found that infection of
pre-immune mice with a virus lacking the majority of the
ectodomain of B5, vvΔB5-gag, was able to induce an anti-Gag-
immune response after a single DNA prime not achieved by a
wild-type virus expressing the same Gag antigen. The anti-Gag
responses elicited by this virus are likely the result of anenhanced ability to spread in the absence of pre-existing anti-B5
antibodies. Importantly, while vvΔB5-gag may have a slight
advantage in the setting of pre-existing immunity, the absence
of the B5 ectodomain and the TK region used to express Gag,
attenuates this virus' ability to grow and spread compared to
vvWT-gag, which is also TK-minus, but has a fully intact B5.
Thus in addition to being a vector that can enhance immune
responses to a foreign protein in the context of pre-existing
immunity to vaccinia, it also is a vaccinia-based vector with
reduced virulence. We focused on cellular immune responses
because the portion of Gag we cloned and expressed in the
recombinant vaccinia viruses lacks its natural N-terminus and
thus Gag particles are not released from infected cells, so little to
no anti-Gag antibody responses can be detected (data not
shown). It is important to point out that our results do not
contradict the previously published findings of Jackson et al.
(2005). In that study, a panel of recombinant vaccinia viruses
lacking various genes (including one that contained a B5R
deletion) and expressing the HIV envelope did not improve the
capacity of the viruses to augment immune responses to the
expressed foreign protein when compared to the parental virus
expressing the same foreign protein. However, they were
examining a very different question than the one we posed in
our study. They were not looking at pre-existing vector
immunity, but rather the effect of the absence of various
vaccinia virus genes on immune responses to a foreign protein
after a prime and boost (Jackson et al., 2005).
Numerous studies have examined methods for enhancing the
immune response to foreign proteins that are expressed by viral
vectors. One effective and commonly used technique is to delete
immune modulatory proteins made by the viral vector. For
example, deletion of the vaccinia virus anti-inflammatory
genes, SPI-1 and SPI-2, increases both the humoral and T-
helper responses to a foreign protein while simultaneously
attenuating the vector (Legrand et al., 2004). In addition, herpes
simplex virus type-1 vectors constructed to lack a viral gene that
interferes with MHC class I expression were found to exhibit
enhanced anti-tumor T cell activity (Todo et al., 2001). Another
important method for enhancing the immune response to a
foreign protein produced by a viral vector is by suppressing the
antiviral immune response. Lieber et al. have shown that
infection with a recombinant adenovirus vector expressing an
IκBα supersuppresor results in reduced production of antiviral
cytokines and enhanced immune responses to the transgene
product (Lieber et al., 1998). Transient deletion of CD4+ T cells
was also found to allow establishment of an adenovirus vector
within its host (Kolls et al., 1996). Most recently, studies have
sought to specifically bias the immune system so as to maximize
the response to a viral vector-induced protein. These have
included viral expression of immune modulatory cytokines,
chemokines, and costimulatory molecules (Ahlers et al., 2003;
Kikuchi et al., 2005; Klas et al., 2006). While each of these
strategies has proven to be effective in naïve animals, it is
difficult to assess how successful they would be in the context
of pre-existing immunity against the viral vector. In addition,
administration of exogenous immune suppressors, or activa-
tors, into humans is accompanied by questions of safety and
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vaccinia immune animals with a viral vector lacking B5 ecto-
domain is that no manipulation of the host immune response is
required.
Our findings that vvΔB5-gag induces a better anti-Gag
immune response than vvWT-gag in pre-immune mice lends
further support to the importance of B5 as a target of EV-
neutralizing antibodies (Bell et al., 2004). Our results imply that
after immunization with a WT vaccinia virus, vvΔB5-gag is not
readily controlled by anti-B5 responses, thus allowing expres-
sion of Gag to occur. Vaccination with a B5R-KO virus, in
contrast, results in the development of an anti-vaccinia immune
response that does not rely on an anti-B5 response. It is only in
this context that vvΔB5-gag is more readily cleared, while the
vvWT-gag virus, with an intact B5 protein, is able to spread and
generate a better anti-Gag immune response. This report
provides the initial groundwork for the extension of vaccinia-
based vector therapies that rely on replication competent
vaccinia virus to individuals with pre-existing immunity against
vaccinia. The consecutive inactivation of additional genes
encoding target proteins for neutralizing antibodies may further
extend the usefulness of such vectors.
Materials and methods
Recombinant vaccinia viruses
Two recombinant viruses (strain IHDJ) expressing a
fragment of Gag from the HXB2 clone of prototype HIV strain
3B (from amino acids 29 to 498) under control of a synthetic
strong early/late vaccinia promoter (Chakrabarti et al., 1997)
were used in the study. The wild-type virus with the Gag gene
inserted into the thymidine kinase gene (TK) (vSIAA-34) was
previously described (Kwak et al., 2004). For this study, we
refer to that virus as vvWT-gag. A B5 mutant virus expressing
the same antigen in the TK region was generated using as the
parental virus a previously constructed virus, vSI-26 (Herrera et
al., 1998), which lacks 80% of the B5 ectodomain. To construct
this virus, plasmid pSI-1724 was used to direct homologous
recombination of the foreign gene into the TK gene, and the
recombinant virus was plaque purified on a TK-minus cell line
in the presence of bromo-deoxyuridine and x-gal. The isolated
virus, vSIHK-36, is referred to in this report as vvΔB5-gag.
Using a rabbit polyclonal antiserum to Gag (Steimer et al.,
1986), Western blots of infected cell lysates showed that Gag is
equally expressed by both viruses (data not shown). A
previously described recombinant vaccinia virus, vSI-14
(Wolffe et al., 1993), which has the entire B5R open reading
frame deleted was also used and is referred to as vvB5R-KO in
this study.
Mice
Female BALB/c (H-2d) were purchased from Charles River
Laboratories and maintained in a pathogen-free microisolator
environment. Six- to eight-week-old female mice were used in
this study.Vaccinations
Mice were immunized once by tail scarification with
approximately 5×106 pfu of WT or 2×107 pfu of vvB5R-KO
viruses. We used this slightly higher dose of the B5R deletion
virus because this virus is attenuated due to its inability to
efficiently make EV and we wanted to ensure the generation of
good anti-vaccinia virus immune responses (see below). Two
weeks later, some groups of mice were primed with 100 μg of
HIV-1 p37gag DNA plasmid (Qiu et al., 1999) intramuscularly.
After 2 additional weeks, mice were intraperitoneally boosted
with approximately 2×106 pfu of vvWT-gag, vvΔB5-gag, or
WT virus. To analyze the primary immune response to Gag, we
sacrificed mice 2 weeks after the boost (see below).
Gag-specific IFN-γ ELISpot
Two weeks after boosting with vvWT-gag, vvΔB5-gag, or
WT, mice were sacrificed and splenocyte suspensions pre-
pared. Red blood cells were lysed and splenocytes resuspended
in complete tissue culture media (DMEM supplemented with
10% FBS (Hyclone), 2 mM glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and 50 μM β-mercaptoethanol).
IFN-γ ELISpot was performed as previously described (Kwak
et al., 2004) using a murine IFN-γ ELISpot kit (R&D Systems).
In brief, 2.5×105 splenocytes were plated into each well in
duplicate and incubated with either Gag class I epitope (1 μM),
Gag class II epitope (10 μM), control peptide LL0 91–99
(1 μM), or control peptide pigeon cytochrome c (10 μM) at
37 °C. All peptides were synthesized and described previously
(Mata and Paterson, 1999; Mata et al., 1998; Pamer et al., 1991;
Shen et al., 2002). Briefly, the Kd-restricted class I Gag peptide
is sequence 197–205 (AMQMLKETI) (Mata et al., 1998) and
the H-2d restricted class II Gag peptide is sequence 253–272
(NPPIPVGEIYKRWIILGLNK) (Mata and Paterson, 1999).
After 24 h, plates were washed and IFN-γ producing cells were
stained with biotinylated anti-IFN-γ antibody, followed by
alkaline phosphatase-conjugated streptavidin and its substrate,
BCIP/NBT chromogen. Plates were washed, and the number of
colored spots quantitated in blinded fashion using a dissection
microscope. The number of positive cells in wells that received
control peptide was subtracted from those that received Gag
peptides.
Pathogenesis of recombinant viruses and vaccinia-specific
immune responses
Mice were infected intranasally with 5×106 pfu of vvWT-
gag or vvΔB5-gag and weight was followed over time. Groups
of three mice infected with each virus were sacrificed at days 3
and 5, and virus titers were quantitated in the lung, spleen, and
liver. Harvested organs were homogenized, and freeze-thawed
three times. Samples were sonicated and titered in duplicate by
serial dilution. Dilutions were added to monolayers of BSC-1
cells and incubated for 2 h at 37 °C. The inoculum was
suctioned off, the wells overlaid with media containing 2.5%
FBS and 1% carboxymethylcellulose, and the plates incubated
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and the plaques counted.
To measure vaccinia-specific immune responses, five mice
from each group were sacrificed 6 weeks post infection. Serum
was harvested by cardiac puncture for humoral immune
measurements and spleens were harvested to determine cellular
immune responses. For humoral immune responses, 96-well
flat-bottomed ELISA plates were coated overnight at 4 °C using
whole cell vaccinia-infected cell lysates in bicarbonate coating
buffer as previously described (Hammarlund et al., 2003; Viner
and Isaacs, 2005). Serial three-fold dilutions of sera were
incubated for 1 h at room temperature. Plates were washed and
incubated with horseradish peroxidase (HRP)-conjugated rabbit
anti-mouse IgGAM (1:2000; Zymed, San Francisco, CA). After
1 h, OPD (Acros Organics, NJ) was added and the reaction was
stopped with 1 M HCl and absorbance measured using an
ELISA reader at 490 nm. For vaccinia-specific IFN-γ
production splenocyte suspensions were prepared from har-
vested spleens. Cells were enriched for lymphocytes by plating
in 6-well plates at 2×106 cells/well, incubating at 37 °C, and
harvesting only the non-adherent cells. After 3 h, cells were
resuspended in complete tissue culture media and IFN-γ
ELISpot was performed using an IFN-γ ELISpot kit. Briefly,
2×105 splenocytes were plated into each well and co-cultured
with 5×104 antigen-presenting cells (APCs). APCs were naïve
splenocytes infected for 1 h at a multiplicity of infection of
3 pfu/cell with vaccinia virus (strain WR) and gamma-irradiated
with ∼1000 rad prior to plating. Uninfected APCs were used to
quantitate nonspecific responses. After 24 h, wells were washed
and plates were incubated overnight with a biotinylated anti-
IFN-γ mAb. IFN-γ producing cells were detected with alkaline
phosphate–streptavidin and BCIP/NBT chromogen substrate.
Positive cells were quantitated using a dissection microscope.
Vaccinia-specific antibody responses after scarification with
wild-type virus or the B5R deletion virus
To examine the anti-vaccinia virus humoral immune
responses after vaccination with the WT or vvB5R-KO viruses,
groups of mice were bled 1 month after the initial vaccinia
vaccination and a direct ELISA using vaccinia-infected cell
lysates was performed as described above. We also tested sera
against individual MV and EV proteins. 96-well plates were
coated with baculovirus-expressed and purified L1 protein
(Aldaz-Carroll et al., 2005b) and A33 protein (Earl et al., 2004)
at 5 μg/ml. Plates were washed, blocked, probed, and developed
as described above, except that HRP-conjugated goat anti-
mouse IgG (1:4000) was used as a secondary antibody, and
TMB (3,3,5,5-tetramethylbenzidene, BD Biosciences) was used
as the substrate. Absorbance was measured at 450 nm. To
further examine the effect of antibody responses in mice
initially vaccinated with the WTor vvB5R-KO viruses and then
boosted with the recombinant Gag-expressing viruses, groups
of mice were bled 2 weeks after the boost and a direct ELISA
using baculovirus-expressed and purified A33 (Earl et al., 2004)
and B5 proteins (Aldaz-Carroll et al., 2005a) was performed as
described above.Statistical analysis
Statistical differences between groups were found using the
Student's paired t test, and a p value of <0.05 was considered
significant.
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